Research & Literature

Pituitary MRI characteristics in 297 acromegaly patients based on T2-weighted sequences.

Potorac I, Petrossians P, Daly AF, et al.

Endocrine-related cancer 2015; (22(2)):169-77 doi:10.1530/ERC-14-0305.

Health Outcomes in Acromegaly: Depression and Anxiety are Promising Targets for Improving Reduced Quality of Life.

Geraedts VJ, Dimopoulou C, Auer M, et al.

Frontiers in endocrinology 2014; (5()):229 doi:10.3389/fendo.2014.00229.

Expression of somatostatin receptor subtype 2 in growth hormone-secreting pituitary adenoma and the regulation of miR-185.

Fan X, Mao Z, He D, et al.

Journal of endocrinological investigation 2015; (38(10)):1117-28 doi:10.1007/s40618-015-0306-7.

Adverse events associated with somatostatin analogs in acromegaly.

Grasso LF, Auriemma RS, Pivonello R, Colao A

Expert opinion on drug safety 2015; (14(8)):1213-26 doi:10.1517/14740338.2015.1059817.

Gamma knife radiosurgery in patients with persistent acromegaly or Cushing's disease: long-term risk of hypopituitarism.

Cohen-Inbar O, Ramesh A, Xu Z, et al.

Clinical endocrinology 2016; (84(4)):524-31 doi:10.1111/cen.12938.

Factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to first-generation somatostatin analogues: an immunohistochemical study.

Iacovazzo D, Carlsen E, Lugli F, et al.

European journal of endocrinology 2016; (174(2)):241-50 doi:10.1530/EJE-15-0832.

Incidence and prevalence of acromegaly in a large US health plan database.

Burton T, Le Nestour E, Neary M, Ludlam WH

Pituitary 2016; (19(3)):262-7 doi:10.1007/s11102-015-0701-2.

Pasireotide: a novel treatment for patients with acromegaly.

Cuevas-Ramos D, Fleseriu M

Drug design, development and therapy 2016; (10()):227-39 doi:10.2147/DDDT.S77999.

Acromegaly.

Dineen R, Stewart PM, Sherlock M

QJM : monthly journal of the Association of Physicians 2017; (110(7)):411-420 doi:10.1093/qjmed/hcw004.

Hypopituitarism.

Higham CE, Johannsson G, Shalet SM

Lancet (London, England) 2016; (388(10058)):2403-2415 doi:10.1016/S0140-6736(16)30053-8.

Pegvisomant: a growth hormone receptor antagonist used in the treatment of acromegaly.

Tritos NA, Biller BM

Pituitary 2017; (20(1)):129-135 doi:10.1007/s11102-016-0753-y.

PREDICTORS OF QUALITY OF LIFE IN 165 PATIENTS WITH ACROMEGALY: RESULTS FROM A SINGLE-CENTER STUDY.

Kreitschmann-Andermahr I, Buchfelder M, Kleist B, et al.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2017; (23(1)):79-88 doi:10.4158/EP161373.OR.

Acromegaly: clinical features at diagnosis.

Vilar L, Vilar CF, Lyra R, et al.

Pituitary 2017; (20(1)):22-32 doi:10.1007/s11102-016-0772-8.

A multivariable prediction model for pegvisomant dosing: monotherapy and in combination with long-acting somatostatin analogues.

Franck SE, Korevaar TIM, Petrossians P, et al.

European journal of endocrinology 2017; (176(4)):421-431.

Somatostatin receptor ligands in the treatment of acromegaly.

Gadelha MR, Wildemberg LE, Bronstein MD, et al.

Pituitary 2017; (20(1)):100-108 doi:10.1007/s11102-017-0791-0.

Complications of acromegaly: cardiovascular, respiratory and metabolic comorbidities.

Pivonello R, Auriemma RS, Grasso LF, et al.

Pituitary 2017; (20(1)):46-62 doi:10.1007/s11102-017-0797-7.

Long-Term Endocrine Outcomes Following Endoscopic Endonasal Transsphenoidal Surgery for Acromegaly and Associated Prognostic Factors.

Babu H, Ortega A, Nuno M, et al.

Neurosurgery 2017; (81(2)):357-366 doi:10.1093/neuros/nyx020.

An intrasellar pituitary adenoma-gangliocytoma presenting as acromegaly.

Lee MH, McKelvie P, Krishnamurthy B, et al.

Endocrinology, diabetes & metabolism case reports 2017; (2017()) doi:10.1530/EDM-17-0035.

Overview of the 2017 WHO Classification of Pituitary Tumors.

Mete O, Lopes MB

Endocrine pathology 2017; (28(3)):228-243 doi:10.1007/s12022-017-9498-z.

Increased Risk of Persistent Glucose Disorders After Control of Acromegaly.

Rochette C, Graillon T, Albarel F, et al.

Journal of the Endocrine Society 2017; (1(12)):1531-1539 doi:10.1210/js.2017-00334.

Biochemical efficacy of long-acting lanreotide depot/Autogel in patients with acromegaly naïve to somatostatin-receptor ligands: analysis of three multicenter clinical trials.

Alquraini H, Del Pilar Schneider M, Mirakhur B, Barkan A

Pituitary 2018; (21(3)):283-289 doi:10.1007/s11102-018-0867-5.

Somatostatin Analogs and Glucose Metabolism in Acromegaly: A Meta-analysis of Prospective Interventional Studies.

Cozzolino A, Feola T, Simonelli I, et al.

The Journal of clinical endocrinology and metabolism 2018; doi:10.1210/jc.2017-02566.

The experience with transsphenoidal surgery and its importance to outcomes.

Honegger J, Grimm F

Pituitary 2018; (21(5)):545-555 doi:10.1007/s11102-018-0904-4.

Adenoma size and postoperative IGF-1 levels predict surgical outcomes in acromegaly patients: results of the Swiss Pituitary Registry (SwissPit).

Kempf J, Schmitz A, Meier A, et al.

Swiss medical weekly 2018; (148()):w14653.

A case of a co-secreting TSH and growth hormone pituitary adenoma presenting with a thyroid nodule.

Adams LH, Adams D

Endocrinology, diabetes & metabolism case reports 2018; (2018()) doi:10.1530/EDM-18-0067.

Radiosurgery as primary management for acromegaly.

Sims-Williams HP, Rajapaksa K, Sinha S, et al.

Clinical endocrinology 2019; (90(1)):114-121 doi:10.1111/cen.13870.

Is GH nadir during OGTT a reliable test for diagnosis of acromegaly in patients with abnormal glucose metabolism?

Dobri G, Niwattisaiwong S, Bena JF, et al.

Endocrine 2019; (64(1)):139-146 doi:10.1007/s12020-018-1805-z.

Acromegaly.

Colao A, Grasso LFS, Giustina A, et al.

Nature reviews. Disease primers 2019; (5(1)):20 doi:10.1038/s41572-019-0071-6.

Patients' perspectives on acromegaly diagnostic delay: a qualitative study.

Sibeoni J, Manolios E, Verneuil L, et al.

European journal of endocrinology 2019; (180(6)):339-352.

Sudden Headache and Blindness Due to Pituitary (Adenoma) Infarction: A Case Report.

Dupont G, Lachkar S, Iwanaga J, et al.

Cureus 2019; (11(2)):e4059 doi:10.7759/cureus.4059.

Arthropathy in acromegaly: a questionnaire-based estimation of motor disability and its relation with quality of life and work productivity.

Fatti LM, Cangiano B, Vitale G, et al.

Pituitary 2019; (22(5)):552-560 doi:10.1007/s11102-019-00966-8.

A Consensus on the Diagnosis and Treatment of Acromegaly Comorbidities: An Update.

Giustina A, Barkan A, Beckers A, et al.

The Journal of clinical endocrinology and metabolism 2020; (105(4)) doi:10.1210/clinem/dgz096.

The Course of Obstructive Sleep Apnea Syndrome in Patients With Acromegaly During Treatment.

Wolters TLC, Roerink SHPP, Drenthen LCA, et al.

The Journal of clinical endocrinology and metabolism 2020; (105(1)) doi:10.1210/clinem/dgz050.

Hypertension and Acromegaly.

Puglisi S, Terzolo M

Endocrinology and metabolism clinics of North America 2019; (48(4)):779-793 doi:10.1016/j.ecl.2019.08.008.

Diagnosis, treatment and follow-up of patients with acromegaly in a clinical practice setting in Spain: the ACROPRAXIS program Delphi survey.

de Pablos-Velasco P, Venegas EM, Álvarez Escolá C, et al.

Pituitary 2020; (23(2)):129-139 doi:10.1007/s11102-019-01012-3.

Italian Association of Clinical Endocrinologists (AME) and Italian AACE Chapter Position Statement for Clinical Practice: Acromegaly - Part 1: Diagnostic and Clinical Issues.

Cozzi R, Ambrosio MR, Attanasio R, et al.

Endocrine, metabolic & immune disorders drug targets 2020; (20(8)):1133-1143 doi:10.2174/1871530320666200127103320.

Italian Association of Clinical Endocrinologists (AME) and Italian AACE Chapter Position Statement for Clinical Practice: Acromegaly - Part 2: Therapeutic Issues.

Cozzi R, Ambrosio MR, Attanasio R, et al.

Endocrine, metabolic & immune disorders drug targets 2020; (20(8)):1144-1155 doi:10.2174/1871530320666200129113328.

Electrophysiological features in acromegaly: re-thinking the arrhythmic risk?

Parolin M, Dassie F, Vettor R, et al.

Journal of endocrinological investigation 2021; (44(2)):209-221 doi:10.1007/s40618-020-01343-0.

Multidisciplinary management of acromegaly: A consensus.

Giustina A, Barkhoudarian G, Beckers A, et al.

Reviews in endocrine & metabolic disorders 2020; (21(4)):667-678 doi:10.1007/s11154-020-09588-z.

Vertebral Fractures Associated with Spinal Sagittal Imbalance and Quality of Life in Acromegaly: A Radiographic Study with EOS 2D/3D Technology.

Cellini M, Biamonte E, Mazza M, et al.

Neuroendocrinology 2021; (111(8)):775-785 doi:10.1159/000511811.

Increased risk of preneoplastic colonic lesions and colorectal carcinoma in acromegaly: multicenter case-control study.

Battistone MF, Miragaya K, Rogozinski A, et al.

Pituitary 2021; (24(1)):96-103 doi:10.1007/s11102-020-01090-8.

A Pituitary Society update to acromegaly management guidelines.

Fleseriu M, Biller BMK, Freda PU, et al.

Pituitary 2021; (24(1)):1-13 doi:10.1007/s11102-020-01091-7.

Progression of acromegalic arthropathy in long-term controlled acromegaly patients: 9 years of longitudinal follow-up.

Pelsma ICM, Biermasz NR, van Furth WR, et al.

The Journal of clinical endocrinology and metabolism 2021; (106(1)):188-200 doi:10.1210/clinem/dgaa747.

Digenic Variants in the FGF21 Signaling Pathway Associated with Severe Insulin Resistance and Pseudoacromegaly.

Stone SI, Wegner DJ, Wambach JA, et al.

Journal of the Endocrine Society 2020; (4(12)):bvaa138 doi:10.1210/jendso/bvaa138.

Discordant GH and IGF-1 Results in Treated Acromegaly: Impact of GH Cutoffs and Mean Values Assessment.

Campana C, Cocchiara F, Corica G, et al.

The Journal of clinical endocrinology and metabolism 2021; (106(3)):789-801 doi:10.1210/clinem/dgaa859.

Prognostic Factors of Acromegalic Patients with Growth Hormone-Secreting Pituitary Adenoma After Transsphenoidal Surgery.

Taweesomboonyat C, Oearsakul T

World neurosurgery 2021; (146()):e1360-e1366 doi:10.1016/j.wneu.2020.12.013.

[Acromegaly and it's cardiovascular implications].

Cadena-Obando DA, Remba-Shapiro I, Abreu-Rosario CG, Mercado M

Revista medica del Instituto Mexicano del Seguro Social 2021; (59(1)):73-80 doi:10.24875/RMIMSS.M21000054.

Clinical Implications of the New WHO Classification 2017 for Pituitary Tumors.

Saeger W, Koch A

Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 2021; (129(3)):146-156 doi:10.1055/a-1310-7900.

The Biochemical Diagnosis of Acromegaly.

Akirov A, Masri-Iraqi H, Dotan I, Shimon I

Journal of clinical medicine 2021; (10(5)) doi:10.3390/jcm10051147.

Differential Diagnosis of Acromegaly: Pachydermoperiostosis Two New Cases from Turkey

Kartal Baykan E, Türkyılmaz A

Journal of clinical research in pediatric endocrinology 2022; (14(3)):350-355 doi:10.4274/jcrpe.galenos.2021.2020.0301.

Global epidemiology of acromegaly: a systematic review and meta-analysis.

Crisafulli S, Luxi N, Sultana J, et al.

European journal of endocrinology 2021; (185(2)):251-263.

Spontaneous Remission of Acromegaly After Pituitary Apoplexy in a Middle-Aged Male.

Alam S, Kubihal S, Goyal A, Jyotsna VP

Ochsner journal 2021; (21(2)):194-199 doi:10.31486/toj.20.0002.

Growth hormone secreting pituitary carcinomas: Case report and review of literature.

Vekaria S, Chen F, Zan E, et al.

Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society 2021; (60-61()):101430 doi:10.1016/j.ghir.2021.101430.

The Future of Somatostatin Receptor Ligands in Acromegaly.

Gadelha MR, Wildemberg LE, Kasuki L

The Journal of clinical endocrinology and metabolism 2022; (107(2)):297-308 doi:10.1210/clinem/dgab726.

Quality of life in patients with acromegaly receiving lanreotide autogel: a real-world observational study.

Bolanowski M, Hubalewska-Dydejczyk A, Kos-Kudła B, et al.

Endokrynologia Polska 2021; (72(5)):512-519 doi:10.5603/EP.a2021.0075.

State of the Art of Patient-reported Outcomes in Acromegaly or GH Deficiency: A Systematic Review and Meta-analysis.

van der Meulen M, Zamanipoor Najafabadi AH, Broersen LHA, et al.

The Journal of clinical endocrinology and metabolism 2022; (107(5)):1225-1238 doi:10.1210/clinem/dgab874.

Diagnosis and Treatment of Acromegaly: An Update.

Ershadinia N, Tritos NA

Mayo Clinic proceedings 2022; (97(2)):333-346 doi:10.1016/j.mayocp.2021.11.007.

High Prevalence of Vertebral Fractures Associated With Preoperative GH Levels in Patients With Recent Diagnosis of Acromegaly.

Frara S, Melin Uygur M, di Filippo L, et al.

The Journal of clinical endocrinology and metabolism 2022; (107(7)):e2843-e2850 doi:10.1210/clinem/dgac183.

Clinical and radiographic assessment of peripheral joints in controlled acromegaly.

Pelsma ICM, Kroon HM, van Trigt VR, et al.

Pituitary 2022; (25(4)):622-635 doi:10.1007/s11102-022-01233-z.

Variables Associated With Body Image Concerns in Acromegaly Patients: A Cross-Sectional Study.

Zhang X, Li Y, Zhong Y, Wang Z

Frontiers in psychology 2022; (13()):733864 doi:10.3389/fpsyg.2022.733864.

Acromegaly and Colorectal Neoplasm: An Update.

Kasuki L, Maia B, Gadelha MR

Frontiers in endocrinology 2022; (13()):924952 doi:10.3389/fendo.2022.924952.

The prevalence of acromegaly is higher than previously reported: Changes over a three-decade period.

Aagaard C, Christophersen AS, Finnerup S, et al.

Clinical endocrinology 2022; (97(6)):773-782 doi:10.1111/cen.14828.

Global psychological assessment with the evaluation of life and sleep quality and sexual and cognitive function in a large number of patients with acromegaly: a cross-sectional study.

Pivonello R, Auriemma RS, Delli Veneri A, et al.

European journal of endocrinology 2022; (187(6)):823-845 doi:10.1530/EJE-22-0263.

Acromegaly: pathogenesis, diagnosis, and management.

Fleseriu M, Langlois F, Lim DST, et al.

The lancet. Diabetes & endocrinology 2022; (10(11)):804-826 doi:10.1016/S2213-8587(22)00244-3.

Impairment in insulin secretion without changes in insulin resistance explains hyperglycemia in patients with acromegaly treated with pasireotide LAR.

Wolf P, Dormoy A, Maione L, et al.

Endocrine connections 2022; (11(12)).

Growth hormone and gastrointestinal malignancy: An intriguing link.

Palui R, Sridharan K, Kamalanathan S, et al.

World journal of gastrointestinal pathophysiology 2023; (14(1)):1-11 doi:10.4291/wjgp.v14.i1.1.

Imaging of pituitary tumors: an update with the 5th WHO Classifications-part 2. Neoplasms other than PitNET and tumor-mimicking lesions.

Tsukamoto T, Miki Y

Japanese journal of radiology 2023; (41(8)):808-829 doi:10.1007/s11604-023-01407-0.

Clinical and prognostic significance of granulation patterns in somatotroph adenomas/tumors of the pituitary: a meta-analysis.

Vuong HG, Dunn IF

Pituitary 2023; (26(6)):653-659 doi:10.1007/s11102-023-01353-0.

Consensus on criteria for acromegaly diagnosis and remission.

Giustina A, Biermasz N, Casanueva FF, et al.

Pituitary 2024; (27(1)):7-22 doi:10.1007/s11102-023-01360-1.

The Importance of Acromegaloid Physical Features for Clinical Practice.

Perić I, Zamolo G, Bezak B, et al.

Case reports in endocrinology 2023; (2023()):5583344 doi:10.1155/2023/5583344.

Analysis of Diffusion-Weighted and T2-Weighted Imaging in the Prediction of Distinct Granulation Patterns of Somatotroph Adenomas.

Tang Y, Xie T, Guo Y, et al.

World neurosurgery 2024; (182()):e334-e343 doi:10.1016/j.wneu.2023.11.107.

Real-world value of cabergoline in the treatment of acromegaly.

Shimon I

Best practice & research. Clinical endocrinology & metabolism 2024; (38(4)):101887 doi:10.1016/j.beem.2024.101887.

Pseudoacromegaly-A challenging entity in the endocrine clinic: A systematic review.

Marques P, Sapinho I, Korbonits M

Clinical endocrinology 2024; (100(6)):542-557 doi:10.1111/cen.15053.

Pituitary Apoplexy: An Updated Review.

Iglesias P

Journal of clinical medicine 2024; (13(9)) doi:10.3390/jcm13092508.

The spectrum of cardiac abnormalities in patients with acromegaly: results from a case-control cardiac magnetic resonance study.

De Alcubierre D, Feola T, Cozzolino A, et al.

Pituitary 2024; (27(4)):416-427 doi:10.1007/s11102-024-01403-1.

Acromegaly management in the Nordic countries: A Delphi consensus survey.

Arlien-Søborg MC, Dal J, Heck A, et al.

Clinical endocrinology 2024; (101(3)):263-273 doi:10.1111/cen.15095.

Every Third Male Patient with Acromegaly Recovers from Hypogonadism after Neurosurgical Treatment.

Derwich-Rudowicz A, Nijakowski K, Biczysko A, et al.

Journal of clinical medicine 2024; (13(18)) doi:10.3390/jcm13185526.

The role of intervention timing and treatment modality in visual recovery following pituitary apoplexy: a systematic review and meta-analysis.

Brown NJ, Patel S, Gendreau J, Abraham ME

Journal of neuro-oncology 2024; (170(3)):469-482 doi:10.1007/s11060-024-04717-z.

Anxiety, depression and acromegaly: a systematic review.

Silvestro O, Lund-Jacobsen T, Ferraù F, et al.

Journal of endocrinological investigation 2025; (48(3)):527-546 doi:10.1007/s40618-024-02483-3.

Ends of the spectrum best practices for early detection and multidisciplinary management of acromegaly.

Cheok SK, Tavakoli-Sabour S, Beck RT, et al.

Journal of neuro-oncology 2025; (171(1)):1-9 doi:10.1007/s11060-024-04833-w.

Endocrine Alterations in Patients With Pachydermoperiostosis.

Stelmachowska-Banaś M, Barry S, Angurala I, et al.

The Journal of clinical endocrinology and metabolism 2025; (110(10)):2818-2831 doi:10.1210/clinem/dgaf050.

Outcomes of transsphenoidal surgery for pituitary adenomas in Spain: a retrospective multicenter study.

Paja M, Soto A, Hanzu FA, et al.

Frontiers in endocrinology 2025; (16()):1529418 doi:10.3389/fendo.2025.1529418.

Hospital procedural volume is inversely linearly associated with complications in endoscopic endonasal transsphenoidal resection of pituitary tumors.

Han JS, Demetriou AN, Dallas J, et al.

Journal of neurosurgery 2025; (143(5)):1377-1386 doi:10.3171/2025.3.JNS242018.

Postoperative Considerations Following Pituitary Surgery: A Guide for Clinicians.

Giraldi EA, Ioachimescu AG

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2025; (31(10)):1339-1345 doi:10.1016/j.eprac.2025.06.018.

Evaluating pituitary tumor management: aligning with pituitary tumor centers of excellence criteria.

Yang JH, Wang WH, Chen HS

Pituitary 2025; (28(5)):91 doi:10.1007/s11102-025-01563-8.

Outcome of acromegalic patients undergoing endoscopic endonasal surgery: collaborative French and Italian cohort, a 25-year experience.

Baussart B, Zoli M, Passeri T, et al.

Neurosurgical review 2025; (48(1)):654.

Medical treatment in acromegaly: a network meta-analysis.

Kaparounaki C, Ilie MD, De Alcubierre D, et al.

European journal of endocrinology 2025; (193(5)):S83-S94 doi:10.1093/ejendo/lvaf221.

Acromegaly in an elderly male with hepatic malignancy: a case report of a diagnostic dilemma.

Sah RK, Devkota D, Sah CK, Pathak A

Annals of medicine and surgery (2012) 2026; (88(1)):819-823 doi:10.1097/MS9.0000000000004375.

Management of endocrine disease: update on the management of pituitary apoplexy.

Biagetti B, Marques P, Ntali G, et al.

European journal of endocrinology 2026; (194(2)):R49-R66 doi:10.1093/ejendo/lvag034.

Acromegaly and clinical manifestations.

Villar-Taibo R, Fernández-Rodríguez E, Bernabéu I

Vitamins and hormones 2026; (131()):153-193 doi:10.1016/bs.vh.2025.10.004.

To test or not to test: what we have learnt from 50 years of dynamic testing in acromegaly.

De Marinis L, Chiloiro S, Mancini A, et al.

Pituitary 2026; (29(2)).

Long-term safety and efficacy of pegvisomant monotherapy for acromegaly: final data from the full ACROSTUDY cohort.

Yuen KCJ, Vila G, Bernabeu I, et al.

Pituitary 2026; (29(3)).

Pituitary adenoma imaging as a determinant of acromegaly diagnosis and outcomes.

Haberbosch L, MacFarlane J, Gillett D, et al.

The Journal of clinical endocrinology and metabolism 2026; (111(Supplement_1)):S89-S106 doi:10.1210/clinem/dgag179.

Acromegaly diagnosis.

Yogi-Morren D, Chanson P

The Journal of clinical endocrinology and metabolism 2026; (111(Supplement_1)):S38-S50 doi:10.1210/clinem/dgag189.

Pathological Classification and Clinical Characteristics of Growth Hormone-Secreting PitNETs.

Li Z, Wu Y, Gao Y, et al.

Neuroendocrinology 2026; 1-16 doi:10.1159/000552989.

Postoperative Pituitary MRI Findings in Acromegaly: A Pictorial Review.

Daskareh M, Abbasi F, Emamzadeh N, et al.

Diagnostics (Basel, Switzerland) 2026; (16(16)) doi:10.3390/diagnostics16162582.